Search alternatives:
linear decrease » linear increase (Expand Search)
lower decrease » larger decrease (Expand Search), we decrease (Expand Search), showed decreased (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 521 - 540 results of 7,084 for search 'significantly ((((lower decrease) OR (linear decrease))) OR (((teer decrease) OR (mean decrease))))', query time: 0.46s Refine Results
  1. 521
    Mean AIV-H9N2 shedding titer (Log<sub>10</sub>) in oropharyngeal swabs.

    Mean AIV-H9N2 shedding titer (Log<sub>10</sub>) in oropharyngeal swabs. by Oumayma Arbani (21001472)

    Published 2025
    Save to List
    Saved in:
  2. 522
    ECoG timescales decrease during spatial attention.

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
    Save to List
    Saved in:
  3. 523
    The proportional change in maximum height for the five study groups.

    The proportional change in maximum height for the five study groups. by Teagan McMahon (20108036)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 524
    Changes in alpha diversity in the weeks before anti-TNF-a treatment.

    Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 525
    Distance-based redundancy analysis (dbRDA) plot performed from the distance-based linear model permutation test (DistLM) that describes the aggregation of sampling stations at every zone according to the year.

    Distance-based redundancy analysis (dbRDA) plot performed from the distance-based linear model permutation test (DistLM) that describes the aggregation of sampling stations at ever... by Francisco Flores-de-Santiago (20391063)

    Published 2025
    Save to List
    Saved in:
  6. 526
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 527
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 528
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 529
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 530
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 531
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 532
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 533
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 534
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 535
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 536
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 537
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 538
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 539
    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales.

    Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)

    Published 2024
    Save to List
    Saved in:
  20. 540
    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN-

    Puriton had the tendency of decreasing expressions of Th1 cell-related cytokines such as IFN- by So-Hyeon Bok (8066696)

    Published 2025
    Save to List
    Saved in:

Search Tools: